MENU
+Compare
NKTX
Stock ticker: NASDAQ
AS OF
Jun 3 closing price
Price
$1.77
Change
+$0.04 (+2.31%)
Capitalization
125.59M

NKTX Nkarta Forecast, Technical & Fundamental Analysis

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies... Show more

NKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NKTX with price predictions
Jun 02, 2025

NKTX in +4.02% Uptrend, growing for three consecutive days on May 29, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NKTX advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where NKTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for NKTX moved out of overbought territory on April 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on June 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NKTX as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NKTX turned negative on May 06, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

NKTX moved below its 50-day moving average on May 30, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on May 27, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.332) is normal, around the industry mean (17.331). P/E Ratio (0.000) is within average values for comparable stocks, (59.245). NKTX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (261.682).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
NKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

NKTX is expected to report earnings to fall 22.05% to -33 cents per share on August 07

Nkarta NKTX Stock Earnings Reports
Q2'25
Est.
$-0.34
Q1'25
Beat
by $0.02
Q4'24
Beat
by $0.05
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.13
The last earnings report on May 14 showed earnings per share of -43 cents, beating the estimate of -44 cents. With 463.68K shares outstanding, the current market capitalization sits at 125.59M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1150 Veterans Boulevard
Phone
+1 905 407-1049
Employees
150
Web
https://www.nkartatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NONOF71.250.74
+1.05%
Novo-Nordisk A/S
SCMWY68.93-0.63
-0.90%
Swisscom AG
BMRRY17.92-0.43
-2.32%
B&M European Value Retail SA
BBBXF0.05N/A
-2.87%
Brixton Metals Corp.
JBAXY12.85-0.42
-3.13%
Julius Baer Group Ltd.

NKTX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with BEAM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTX
1D Price
Change %
NKTX100%
+2.31%
BEAM - NKTX
49%
Loosely correlated
+4.26%
KYMR - NKTX
48%
Loosely correlated
+1.04%
CRBU - NKTX
48%
Loosely correlated
+7.70%
FATE - NKTX
47%
Loosely correlated
+4.62%
IMNM - NKTX
47%
Loosely correlated
+2.21%
More